NCT02603224View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

MRG-201

Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.

DRUG

Placebo

Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.

Trial Locations (1)

H2K 4L5

Innovaderm Research, Inc., Montreal

All Listed Sponsors
lead

miRagen Therapeutics, Inc.

INDUSTRY

NCT02603224 - Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers | Biotech Hunter | Biotech Hunter